Search
Close this search box.
Logo Asphalion

BREAKING NEWS!! | EMA recommends HIPRA Covid19 vaccine approval

March 30, 2023

EMA’s human medicines committee (CHMP) has recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and above who have been vaccinated with an mRNA COVID-19 vaccine.

Bimervax, developed by HIPRA, contains a protein produced in the laboratory that consists of part of the SARS-CoV-2 spike protein from the Alpha and Beta virus variants.

The CHMP concluded that sufficiently robust data on the quality, safety and immunogenicity of the vaccine are now available to recommend its marketing authorisation in the EU.

We would like to congratulate HIPRA and everyone else involved in the development of the vaccine!!!

At ASPHALION, we are deeply proud to have contributed to this achievement as Regulatory partners throughout the whole process.

You can check here for further information:

https://www.ema.europa.eu/en/news/ema-recommends-approval-bimervax-covid-19-booster-vaccine

La EMA recomienda la autorización de la vacuna española de Hipra frente a la COVID-19 | Agencia Española de Medicamentos y Productos Sanitarios (aemps.gob.es)

 

 

 

Search News & Events

  • Filter by category

Share

Related news and events

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting